Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Use of alternative care sites during the COVID-19 pandemic in the city of Buenos Aires, Argentina.
Ferrante D, Macchia A, González Villa Monte GA, Battistella G, Baum A, Zingoni P, Angeleri P, Biscayart C, Walton C, Marcó FF, Esteban S, Mariani J, Bernaldo de Quirós FG. Ferrante D, et al. Among authors: biscayart c. Public Health. 2021 May;194:14-16. doi: 10.1016/j.puhe.2021.02.022. Epub 2021 Mar 5. Public Health. 2021. PMID: 33845273 Free PMC article.
Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials.
Macchia A, Ferrante D, Bouzas MB, Angeleri P, Biscayart C, Geffner J, Mammana L, Zapiola I, López EL, Gentile A, Varese A, Mazzitelli I, García FDD, Sharff D, Lucconi V, Sujansky P, Mariani J, de Quirós FGB. Macchia A, et al. Among authors: biscayart c. Lancet Reg Health Am. 2022 May;9:100196. doi: 10.1016/j.lana.2022.100196. Epub 2022 Feb 2. Lancet Reg Health Am. 2022. PMID: 35128512 Free PMC article.
Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population.
Kundro MA, Losso MH, Macchia A, Pastor I, Alonso Serena M, Gestoso C, Moreno Macías L, Crupi F, Acosta MC, Ivalo S, Ghioldi M, Bouzas MB, Mammana L, Zapiola I, Mazzitelli I, Varese A, Geffner J, Biscayart C, Angeleri P, Lopez E, Gentile A, Ferrante D, de Quiros FGB. Kundro MA, et al. Among authors: biscayart c. Public Health Pract (Oxf). 2022 Dec;4:100313. doi: 10.1016/j.puhip.2022.100313. Epub 2022 Sep 6. Public Health Pract (Oxf). 2022. PMID: 36090797 Free PMC article.
The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? - Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI).
Biscayart C, Angeleri P, Lloveras S, Chaves TDSS, Schlagenhauf P, Rodríguez-Morales AJ. Biscayart C, et al. Travel Med Infect Dis. 2020 Jan-Feb;33:101567. doi: 10.1016/j.tmaid.2020.101567. Epub 2020 Jan 30. Travel Med Infect Dis. 2020. PMID: 32006657 Free PMC article. No abstract available.
Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.
Biscayart C, Carrega ME, Sagradini S, Gentile A, Stecher D, Orduna T, Bentancourt S, Jiménez SG, Flynn LP, Arce GP, Uboldi MA, Bugna L, Morales MA, Digilio C, Fabbri C, Enría D, Diosque M, Vizzotti C. Biscayart C, et al. Vaccine. 2014 Mar 5;32(11):1266-72. doi: 10.1016/j.vaccine.2014.01.015. Epub 2014 Jan 21. Vaccine. 2014. PMID: 24456625
Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina.
Vizzotti C, Harris JB, Aquino A, Rancaño C, Biscayart C, Bonaventura R, Pontoriero A, Baumeister E, Freire MC, Magariños M, Duarte B, Grant G, Reef S, Laven J, Wannemuehler KA, Alvarez AMR, Staples JE. Vizzotti C, et al. Among authors: biscayart c. BMC Infect Dis. 2023 Mar 17;23(1):165. doi: 10.1186/s12879-023-08114-1. BMC Infect Dis. 2023. PMID: 36932346 Free PMC article.
11 results